Summary
- Veracyte has a broad diagnostics offering that spans across multiple domains of complex disease.
- We are most attracted to its prostatic biopsy segment, obtained through its acquisition of Decipher Bio in FY21.
- Here, we examined this offering in-line with additional names in the prostate disease segment of our coverage universe.
- Net-net, shares look expensive at this point, and we rate the stock neutral until more clarity from its FY22 numbers.
For further details see:
Veracyte: Building Momentum Around Decipher, Awaiting FY22 Numbers Before Entry